BACK TO TOP
KSE100
171,115.82
-1778.45
(-1.03%)
KSE100PR
52,304.80
-552.93
(-1.05%)
ALLSHR
102,630.81
-743.98
(-0.72%)
KSE30
51,478.54
-641.56
(-1.23%)
KMI30
245,731.79
-3035.82
(-1.22%)
BKTI
47,279.59
-660.98
(-1.38%)
OGTI
35,704.94
-598.06
(-1.65%)
KMIALLSHR
66,650.31
-541.20
(-0.81%)
PSXDIV20
79,163.91
-560.90
(-0.70%)
UPP9
60,585.65
-695.66
(-1.14%)
NITPGI
45,586.52
-569.04
(-1.23%)
NBPPGI
49,531.01
-637.85
(-1.27%)
MZNPI
30,235.06
-350.90
(-1.15%)
JSMFI
42,097.48
-354.64
(-0.84%)
ACI
22,609.69
-253.52
(-1.11%)
JSGBKTI
72,548.24
-1005.30
(-1.37%)
HBLTTI
18,330.55
07-05-2026
5.87
(0.03%)
MII30
22,197.30
-240.89
(-1.07%)
Liven Pharma Limited
PHARMACEUTICALS
Rs.38.01
-0.12
(-0.31%)
1D
1M
6M
YTD
1Y
3Y
5Y
^ As of Fri, May 8, 2026 4:39 PM
REG
DFC
CSF
ODL
Open
37.99
High
38.48
Low
37.50
Volume
37,823
CIRCUIT BREAKER
34.32 — 41.94
DAY RANGE
37.50 — 38.48
52-WEEK RANGE ^
27.82 — 80.80
Ask Price
0.00
Ask Volume
0
Bid Price
0.00
Bid Volume
0
LDCP
38.13
VAR
25.00
HAIRCUT
32.50
P/E Ratio (TTM) **
N/A
1-Year Change * ^
-27.42%
YTD Change * ^
-26.86%

No record found

No record found

No record found

Market data powered by capitalstake.com. Provided by PSX. ** Based on unconsolidated financials
  * Returns not adjusted for payouts
  ^The historical stock prices have been adjusted to reflect stock splits to ensure comparability over time.

Company Profile

BUSINESS DESCRIPTION

Liven Pharma Limited was incorporated in Pakistan as a private Limited Company on October 21, 1991 and was converted into a public limited company on April 30, 1992 under the Companies Ordinance, 1984 (Repealed with the enactment of the Companies Act, 2017). The principal activity of the Company is the manufacturing of pharmaceuticals and allied products.

KEY PEOPLE
Kashif Hussain SiddiquieCEO
Atif Hussain SiddiqiChairman
Muhammad SaeedCompany Secretary
ADDRESS

49-Km, Multan Road, Lahore

WEBSITE

www.liven-pharma.com

REGISTRAR

F.D. Registrar Services SMC (Pvt.) Ltd., 1705,17th Floor, Saima Trade Tower A, I.I. Chundrigar Road, Karachi

AUDITOR

M/s Reanda Haroon Zakaria Aamir Salman Rizwan & Company, Chartered Accountants

Fiscal Year End

June

Equity Profile

Market Cap (000's)
4,296,664.35
Shares
113,040,367
Free Float
11,304,037
Free Float
10.00%

Announcements

Financial Results
Board Meetings
Others
DateTitleDocument
Apr 29, 2026Financial Results for the 3rd Quarter Ended 31st March 2026 View   PDF
Mar 9, 2026Condensed Interim Financial Statements for the Half Year ended December 31, 2025 (with shariah compliant disclosure) View   PDF
Feb 27, 2026Condensed Interim Financial Statements for the Half Year ended December 31, 2025. View   PDF
Feb 27, 2026Financial Results for the half year ended December 31, 2025 View   PDF
Jan 2, 2026Financial results for the quarter ended September 30, 2025. View   PDF
DateTitleDocument
Apr 23, 2026Board Meeting for the 3rd Quarter Financials of 2025-26 View   PDF
Feb 19, 2026Board Meeting for Accounts for the Period Ended 31st December 2025 View   PDF
Jan 1, 2026Extracts of resolution passed in the board of directors meeting of Liven Pharma Limited - December 30, 2025 View   PDF
Dec 26, 2025Board meeting for the consideration of Quarterly accounts for the period ended September 30, 2025 View   
Dec 22, 2025Board Meeting other than financial results View   PDF
DateTitleDocument
Mar 11, 2026Disclosure of Interest by a Director CEO, or Executive of a listed company and their Spouses and the Substantial Shareholders u/c 5.6.1.(d) of PSX Regulations View   
Mar 11, 2026Disclosure of Interest by a Director CEO, or Executive of a listed company and their Spouses and the Substantial Shareholders u/c 5.6.1.(d) of PSX Regulations View   
Mar 11, 2026Disclosure of Interest by a Director CEO, or Executive of a listed company and their Spouses and the Substantial Shareholders u/c 5.6.1.(d) of PSX Regulations View   
Feb 18, 2026Disclosure of Interest by a Director CEO, or Executive of a listed company and their Spouses and the Substantial Shareholders u/c 5.6.1.(d) of PSX Regulations View   
Feb 18, 2026Disclosure of Interest by a Director CEO, or Executive of a listed company and their Spouses and the Substantial Shareholders u/c 5.6.1.(d) of PSX Regulations View   

Financials

All numbers in thousands (000's) except EPS

Annual
Quarterly
2025202420232022
Sales127,272245,093
Profit after Taxation(584,460)41,744(12,327)(14,291)
EPS(8.37)1.04(1.02)(1.18)
Q3 2026Q2 2026Q1 2026Q3 2025
Sales29,24754,5598,82114,755
Profit after Taxation(3,956)28,210(30,157)(9,621)
EPS(0.03)(0.30)(0.32)(0.10)
Data powered by Capital Stake. To provide comparable data, information might have been standardized. The data presented may therefore differ from issuer's annual report and 'as reported' data should be obtained directly from the source issuer. See the Capital Stake Terms of Use.

Ratios

2025202420232022
Gross Profit Margin (%)14.1125.46
Net Profit Margin (%)(459.22)17.03
EPS Growth (%)(901.72)202.3513.562.48
PEG0.010.04(1.06)(4.29)

Payouts

Financial Reports